Free Trial

CytomX Therapeutics (CTMX) News Today

$1.38
-0.08 (-5.48%)
(As of 06/14/2024 ET)
CytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below Fifty Day Moving Average of $2.14
CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Fifty Day Moving Average of $2.14
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy reco
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Large Growth in Short Interest
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 8,750,000 shares, an increase of 143.1% from the April 30th total of 3,600,000 shares. Based on an average daily trading volume, of 6,480,000 shares, the short-interest ratio is presently 1.4 days.
CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Overweight at Piper Sandler
Piper Sandler upgraded CytomX Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $2.25 to $3.50 in a research report on Tuesday.
CytomX Therapeutics Inc.
StockNews.com Upgrades CytomX Therapeutics (NASDAQ:CTMX) to Buy
StockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Hold" from Analysts
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average recommendation of "Hold" by the five research firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and two have assigned a buy ratin
Why Is CytomX (CTMX) Stock Down 43% Today?
CytomX Therapeutics (NASDAQ:CTMX) PT Raised to $3.59
BMO Capital Markets raised their price objective on shares of CytomX Therapeutics from $3.25 to $3.59 and gave the stock a "market perform" rating in a research report on Thursday.
CytomX Therapeutics (NASDAQ:CTMX) Rating Reiterated by HC Wainwright
HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Thursday.
CytomX Therapeutics (NASDAQ:CTMX) Lifted to Outperform at Wedbush
Wedbush upgraded shares of CytomX Therapeutics from a "neutral" rating to an "outperform" rating and set a $8.00 target price for the company in a research note on Thursday.
CytomX Therapeutics (NASDAQ:CTMX) Raised to Buy at Jefferies Financial Group
Jefferies Financial Group raised CytomX Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from $2.50 to $8.00 in a report on Monday.
CytomX Therapeutics (CTMX) Scheduled to Post Earnings on Wednesday
CytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.
CytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 16,565 call options on the company. This is an increase of 7,197% compared to the average daily volume of 227 call options.
BMO Capital Markets Reaffirms "Market Perform" Rating for CytomX Therapeutics (NASDAQ:CTMX)
BMO Capital Markets restated a "market perform" rating and set a $3.25 target price on shares of CytomX Therapeutics in a report on Wednesday.
Why Is CytomX (CTMX) Stock Up 180% Today?
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Update
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,590,000 shares, a growth of 8.1% from the March 31st total of 3,320,000 shares. Based on an average trading volume of 905,200 shares, the short-interest ratio is currently 4.0 days.
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by StockNews.com
StockNews.com cut CytomX Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday.
CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Neutral at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Monday.
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX) General Counsel Sells 5,268 Shares
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) General Counsel Lloyd A. Rowland sold 5,268 shares of the business's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $11,010.12. Following the transaction, the general counsel now owns 117,728 shares in the company, valued at $246,051.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Research Analysts Issue Forecasts for CytomX Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities research analysts at Wedbush issued their FY2028 earnings estimates for shares of CytomX Therapeutics in a research note issued on Tuesday, March 12th. Wedbush analyst R. Driscoll forecasts that the biotechnology company will post e

CTMX Media Mentions By Week

CTMX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CTMX
News Sentiment

1.15

0.90

Average
Medical
News Sentiment

CTMX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CTMX Articles
This Week

4

2

CTMX Articles
Average Week

Get CytomX Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CTMX) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners